HRAS, HRas proto-oncogene, GTPase, 3265

N. diseases: 698; N. variants: 29
Disease: Pancreatic carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. 31227505 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE Obese mice with KRAS (KC) mutation in the pancreas fed with high-fat calorie diet (HFCD) exhibit severe deficiencies in the NK cell expansion and function at the pre-neoplastic stage of pancreatic cancer. 29977235 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. 28607485 2017
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 AlteredExpression disease BEFREE Genetic mutations, such as activation of the KRAS2 oncogene, inactivation of the tumor-suppressor gene CDKN2A, inactivation of the tumor-suppressor gene TP53 and deleted in pancreatic cancer 4 (DPC4) gene defects are seen in those with pancreatic cancer. 23393682 2012
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 Biomarker disease BEFREE CAPAN2 (G12 V) pancreatic cancer xenografts served as a cellular KRAS2 mismatch control. 20232877 2010
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. 19208745 2009
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE LigAmp quantification of mutant KRAS2 in pancreatic juice differentiates pancreatic adenocarcinoma from chronic pancreatitis, and may be a useful early detection tool for pancreatic cancer. 18075308 2008
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE KRAS2 mutations were also detected in pancreatic duct juice from patients with pancreatic cancer. 15782177 2004
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE The sensitivity, specificity, positive and negative predictive values of serum serum KRAS2 mutations for the diagnosis of pancreatic cancer were 47, 87, 85 and 52%, respectively. 12189555 2002
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE In this prospective trial performed in nonselected patients, mutations of the ki-ras gene were detected in 38.1% of cases with pancreatic cancer. 12409332 2002
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE At present, K-ras-2 mutation is not useful for differentiating pancreatic cancer from chronic pancreatitis or the identification of patients with chronic pancreatitis at risk for malignant transformation. 11677475 2001
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 Biomarker disease BEFREE The results from currently completed studies on the detection of mutated KRAS2 in patients with colorectal and pancreatic cancer are promising, and the potential usefulness of KRAS2 as a clinically important tumor marker should encourage future research. 10873061 2000
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE Point mutations of the Ki-ras gene at codon 12 have been frequently identified in pure pancreatic juice of patients with pancreatic cancer in studies examining pancreatic cancer tissues. 8536860 1996
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 Biomarker disease BEFREE Isoprenylation inhibitors of p21ras, such as SV, are expected to be useful for the treatment of pancreatic cancer. 8063617 1994
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. 8157353 1994
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE The prevalence of Kirsten (Ki)-ras gene mutations was studied in 105 paraffin-embedded tissues obtained from 40 patients with pancreatic cancer, 48 with bile duct carcinoma (19 distal, 6 middle, and 23 proximal), 16 with ampullary carcinoma and 1 with duodenal cancer, by in vitro amplification of target sequences by the polymerase chain reaction (PCR). 1741644 1991
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 GeneticVariation disease BEFREE Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. 2110130 1990
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 AlteredExpression disease BEFREE Activation of c-Ki-ras gene in human pancreatic cancer. 3932275 1985